Phase I Investigational Group
Our priority is to provide investigational agents that are supported by strong experimental and preclinical data to a patient population for which standard therapy is ineffective. We care for our patients with compassion, and we respect their courageous volunteerism to participate in clinical research. We are committed to maintaining the integrity of scientific research through the
Dana-Farber/Harvard Cancer Center and contributing to the future of cancer therapeutics.
Who Are We?
Daniel C. Cho, MD
Susan Pandya MD
Research Nurse: Sue Gotthardt RN, OCN
Clinical Research Specialist: Janine Morrissey
Clinical Research Assistants: Felicia Nguyen; Kimiko Kossler
Administrative Assistant: Rena Flambo
Phase I Clinical Trials
As members of the
Dana-Farber/Harvard Cancer Center (DF/HCC), the Phase I Investigational Group offers several agents with various mechanisms of action. The list of options varies and is updated accordingly. Please contact
Sue Gotthardt RN, OCN at (617) 632-9272 for more information.